Background {#Sec1}
==========

Chronic kidney disease (CKD) is a global public health issue. In New Zealand, end stage kidney disease (ESKD) alone accounts for 1-2% of total health care expenditure, a figure comparable to that in the United Kingdom \[[@CR1], [@CR2]\]. The group with highest attributable risk of progressive CKD is those with diabetes mellitus, and this risk is exacerbated by hypertension, obesity and dyslipidaemia \[[@CR3], [@CR4]\]. In addition, CKD is an independent risk factor for cardiovascular (CV) morbidity and mortality through reduced glomerular filtration rate (GFR) and proteinuria \[[@CR5], [@CR6]\]. In New Zealand, indigenous groups (Maori and Pacific peoples) are over represented in their rates of ESKD, accounting for 44% and 29% of those commencing renal replacement therapy in New Zealand, respectively \[[@CR7]\]. These indigenous groups also have highest prevalence of CKD and associated risk factors for progression.

It is generally accepted that early detection and effective management of CKD is the prime strategy to reduce progression to ESKD, decrease CV morbidity and mortality, and ultimately limit resource consumption \[[@CR3], [@CR8]--[@CR10]\]. However despite this knowledge, efforts to manage CKD have not proven effective and the number of patients reaching ESKD continues to increase. Within New Zealand, there are numerous reported barriers that hamper effective management of CKD in the community including socio-economic factors, poor accessibility to primary care, poor health literacy, lack of knowledge of CKD and sub-optimally controlled diabetes and blood pressure \[[@CR11], [@CR12]\]. Alternative models of healthcare delivery are needed to address these issues.

A promising intervention is adjunctive support from nephrology Nurse Practitioners (NPs), which has been recently shown to reduce the rate of CKD progression and improve renal outcomes \[[@CR13]\]. Although this intervention can be regarded as multifaceted, a key element in the role of NPs is coaching to improve self-management by patients. Although the researchers in the aforementioned study did not assess for change in self-management, there have been other randomized control trials (RCTs) involving specifically designed self-management interventions for CKD patients. These have shown measurable improvements in health behaviours and a reduction in the duration and number of hospital admissions \[[@CR14]\], although a recent systematic review of literature has highlighted the small effect of self-management interventions upon level of adherence \[[@CR15]\].

In 2010 the New Zealand Ministry of Health funded several initiatives to improve outcomes for New Zealanders with CKD through more effective management in the primary care setting. In New Zealand, secondary and tertiary services such as nephrology are provided free of charge to all patients through public hospitals funded by taxation. By contrast, primary care (where most CKD is managed) is provided in private medical practices, where consultations are only partially publicly subsidized. In this article, we describe a quality improvement intervention involving collaboration between a regional nephrology service and local primary care clinicians to manage a group of patients with CKD at high risk of progression. The intervention utilized the resource of a nephrology NP, who in New Zealand is a highly-trained specialist nurse practicing autonomously and able to assess, diagnose and prescribe within their scope of practice \[[@CR16]\]. The Ministry of Health funded the time of the NP working with clinicians in their primary care practice, thus enabling the service to be free to the patients.

In this study, we present an evaluation of this intervention in order to demonstrate the clinical potential of the model of care. We employed the reporting framework suggested by the Standards for Quality Improvement Reporting Excellence (SQUIRE) publication guidelines for reporting healthcare quality improvement research (<http://squire-statement.org/assets/pdfs/SQUIRE_guidelines_table.pdf>) \[[@CR17]\].

Methods {#Sec2}
=======

Ethical issues {#Sec3}
--------------

The study was approved by the Regional Ethics Committee (IRB00008714) of the New Zealand Ministry of Health (IORG0000895), conditional upon local ethics committee approval which was granted by the Institutional Review Board of the Hawke's Bay District Health Board after a full review of the study protocol. Patients were invited to participate in the intervention, given verbal and written information regarding the study and what their involvement would include, and informed that they were able to withdraw from participation at any stage.

Setting {#Sec4}
-------

The geographical setting for this study was Hawke's Bay, New Zealand, a rural district situated on the east coast of New Zealand with a population of approximately 170,000. The population of Hawke's Bay is notable for a high degree of socioeconomic deprivation, with 26% of the population in the lowest two national deciles of deprivation. The area is also notable for a high prevalence of New Zealand Maori (the indigenous ethnic group), comprising 25% of the population compared to 15% nationally.

The intervention in this study was conducted by Hawke's Bay District Health Board Nephrology Service in collaboration with two primary care practices located in the highest areas of socioeconomic deprivation in the region. Each practice served a catchment at the time of between 5000--7000 people, with clinicians that included General Practitioners (GPs) and practice nurses, registered nurses employed to work with GPs within the practice.

Patients were studied over a 12 month period, with an accrual period from 1^st^ June 2011 to 15^th^ September 2011.

Planning the intervention {#Sec5}
-------------------------

Patients were screened and recruited through the primary care practices. Inclusion criteria required that all of the following conditions were met: 'high risk of CKD progression' (as defined below), age \>18 years, diagnosis of type two diabetes mellitus, hypertension, and albuminuria defined as an albumin to creatinine ratio (ACR) \>30 mg/mmol on at least three occasions separated by at least 1 week \[[@CR18]\]. The main exclusion criterion was CKD due to renal parenchymal disease other than diabetic nephropathy. Patients at \"high risk of CKD progression\" were defined as those with at least 12 months of uncontrolled diabetes and/or hypertension (glycoslyated haemoglobin (HbA1c) \>8% and blood pressure (BP) \>140/90 mmHg \[[@CR19], [@CR20]\]) *and* a history of poor attendance and engagement with their GP (history of unplanned non-attendance of 25% or more of scheduled appointments over the course of 12 months). Over 500 patients were identified from the initial screen within the practices and fifty-four high risk patients were identified by the primary care teams as also meeting the criteria for poor attendance. These fifty-four were given written information and invitation to participate by their GP or practice nurse. All were subsequently re-contacted by phone to answer any questions, and offered an initial assessment. Fifty two patients subsequently enrolled and participated in the study (Figure [1](#Fig1){ref-type="fig"}).Figure 1**Patient flow.**

The intervention involved a series of sessions led by the nephrology NP with the assistance of the practice nurse. Patients were seen fortnightly for 12 weeks by the NP and the practice nurse, followed by a monitoring phase to 12 months. At baseline, a comprehensive patient history, health literacy and self-management assessment, physical assessment, and laboratory review was performed. Patient history included: medical history, family and social history and lifestyle behaviours including diet, smoking status, salt intake, exercise, and current knowledge of condition and medication. Physical assessment included office measurement of BP according to standardised protocol (JNC 7 \[[@CR21]\]), pulse, height, weight, review of home capillary blood sugar records, and clinical cardiac assessment, conducted by the NP. Laboratory review included HbA1c, serum creatinine, estimated glomerular filtration rate (GFR), ACR and serum lipid levels.

Initial sessions involved tailored education and the development of individualised care plans based on best practice guidelines and using self-management and patient-centered theory utilizing the Flinders Chronic Care model \[[@CR22]\]. A detailed patient education package was developed for the study and included information on diabetes and its complications, blood pressure management, lifestyle modifications, medication adherence, smoking cessation and dietary advice including low salt intake (dietary sodium intake less than 2.3 g/day). All patients were also given a booklet on self-management developed for the study where they could record all clinical results, self-care goals, individualised medication charts and other important information.

Subsequent sessions involved implementation of the individualized care plans, re-assessment of patients and management plan changes and implementations as required. A stepwise BP protocol was developed for the project with titration of antihypertensives at each fortnightly review to target a BP of 130/80 mmHg \[[@CR19], [@CR20], [@CR23]\]. The protocol of medication escalation involved the stepwise addition of angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB), thiazide diuretic, calcium channel blocker, and beta blocker or alpha blocker. Patients were provided with free transport to their study appointments, and all medications subjected to usual patient payments and subsidies without additional cost or reimbursement. All patients in the study continued to receive usual health care (appointments as requested by patients or scheduled chronic disease management routine appointments, which are in general less than 15 minutes and 3 monthly at most) from their GP and primary health care team. Patients underwent baseline and three monthly assessments of study end-points over the period of observation. All patient information and results was entered directly into the primary care health care record.

Planning the study of the intervention {#Sec6}
--------------------------------------

We chose a validated method of measuring and describing the co-morbidities and multi-morbidity in the patient cohort. We extracted co-morbidity data from the medical history of patient records, and classified multi-morbidity using the Cumulative Illness Rating Scale (CIRS) \[[@CR24]\]. This scale has been validated and applied in primary care settings, and has been used widely including the Australasian setting \[[@CR25]\]. The scale rates the presence and severity of illness in 14 organ systems to provide an index of total chronic medical illness burden \[[@CR26]\]. In this study, we assessed multimorbidity using 3 operational definitions: namely, 2 or more diagnoses (or CIRS domains), 3 or more diagnoses (or CIRS domains), and 4 or more diagnoses (or CIRS domains). We assessed the socioeconomic status of the patient cohort using the NZDep score, which combines nine variables from the census that reflect eight domains of deprivation (income, home ownership, social support, employment, academic qualifications, living space, access to a telephone, access to a car). The index provides a score for each meshblock in New Zealand, which are defined geographical areas defined by Statistics New Zealand containing a median number of approximately 87 people in 2006. The NZDep score divides New Zealand into deciles, e.g. a value of 10 indicates the meshblock is in the most deprived 10% of the New Zealand population, and a value of 1 indicates that the meshblock is in the least deprived \[[@CR27]\].

We assessed the outcomes of implementing the quality improvement program through the attendance of the participants to appointments, the attendance of both the NP and the practice nurse for the combined clinics, and staff satisfaction.

We measured the overall clinical impact of the quality improvement program through assessment of study outcomes over the 12 month period of the intervention. Measurements of outcomes (other than for health knowledge, medication knowledge, and self-management) were made at baseline, and endpoints consisted of measurements at 3, 6, 9 and 12 months. Measurements of health knowledge, medication knowledge, and self-management were made at baseline, and endpoints consisted of measurements at 3 and 12 months.

The primary outcome was proteinuria, assessed as the ACR on a random urine specimen taken prior to or at the combined clinic consultation. The secondary outcomes were: estimated GFR as assessed from serum creatinine and the 175 4-variable MDRD equation \[[@CR28]\] (which to date remains the standard method rather than the CKD-EPI formula throughout New Zealand), and 5-year absolute cardiovascular risk (defined as the likelihood of a cardiovascular event over 5 years) \[[@CR23]\].

We also assessed 'intermediary' secondary outcomes. These outcomes were either related to processes of care, or related to clinical outcomes accepted as being intermediate on casual pathways leading to either progression of CKD or to increased cardiovascular risk. Such outcomes were chosen as being the most likely mechanisms through which the study intervention might improve outcomes.

For intermediary secondary outcomes related to the participant, we assessed BP according to standardised protocol (JNC 7 \[[@CR21]\]), serum total cholesterol, BMI, HbA1c and the prevalence of active smoking through patient clinical records. We assessed overall self-management, overall medical knowledge (knowledge of condition and medication), adherence to medication and adoption of a healthy lifestyle through a self-management reporting scale (Partners In Health Score, PIH score) \[[@CR29]\]. The PIH score and questionnaire was developed for the Australian healthcare context, and is used to assess changes in patient self-management knowledge, skill and ability. The assessments are made from both the patient's own perspective and from the perspective of the treating clinician. The ratings span across twelve domains, or areas of patient knowledge and health-related behaviour. The PIH scores provide a validated longitudinal record of how well patients are coping with and managing their chronic conditions \[[@CR29]\].

For intermediary secondary outcomes related to the provider, we assessed prescribing patterns through patient clinical records.

Laboratory measurements were made in a central laboratory using standardized equipment (Abbott Aeroset®, Abbott Laboratories (N.Z.) Limited, Auckland, New Zealand). Serum creatinine assays were performed using the Jaffe method, and calibrated to isotope dilution mass spectroscopy.

Methods evaluation and analyses {#Sec7}
-------------------------------

The study data are in the form of a cross-sectional time-series, otherwise known as a panel, with repeated clinical observations obtained from the same patient over time. The data produce an unbalanced panel, as a result of missing observations pertaining to both truly missing data and also observations that are recorded during some months but not others. Of note, all study data from all participants were modelled, including baseline and follow-up results for those who died and dropped out, up until the time of their termination within the study.

We conducted the analysis of study data using regression models within Stata 12.1 MP software (College Station, TX, USA). For continuous data, we used linear models (xtreg procedure) and for categorical ones we used logistic models (xtlogit procedure). To account for internal correlation between repeated patient observations, a random effect model was used for each dependent variable that included all data from all time periods simultaneously, with observations over time from the same patient sharing the same random effects, assuming different random effects for different patients. To account for non-response bias, regression coefficients were estimated using the maximum likelihood method. Time was modelled as a continuous variable, and all coefficients are the modelled change in each parameter per month, with the p value referring to the significance of this change over time.

Results {#Sec8}
=======

Participants {#Sec9}
------------

Of the original 52 participants, 36 were still available for follow-up 12 months later (see Figure [1](#Fig1){ref-type="fig"}). Baseline clinical characteristics of participants are provided in Table [1](#Tab1){ref-type="table"}, and details of their total chronic medical illness burden in Additional file [1](#MOESM1){ref-type="media"}: Table S1. Socio-economic status of participants is described in Table [2](#Tab2){ref-type="table"}, and illustrates the high level of deprivation with 84% of participants living in the 9 or 10^th^ decile.Table 1**Clinical characteristics of the study cohort at baseline**VariableNumber*N*52PracticeA28 (54)B24 (46)AgeYears57.5 (47--64)GenderMale25 (48)Female27 (52)EthnicityNew Zealand European5 (10)Cook Island Maori/Samoan10 (19)New Zealand Maori37 (71)Appropriate secondary specialist care15 (29)Total chronic medical illness burdenCIRS Score6.92 (2.27)2 or more diagnoses (CIRS domains)%333 or more diagnoses (CIRS domains)%34 or more diagnoses (CIRS domains)%0Albumin to creatinine ratiomg/mmol34.9 (14.2-150.9)5-year absolute cardiovascular risk%20 (15--27)Estimated GFRmL/min/1.73 m^2^63 (48--77)Systolic BPmmHg150 (144.5-160)Diastolic BPmmHg90 (80--110)Serum total cholesterolmmol/L5.25 (4.1-6)Glycosylated haemoglobin%8.8 (7.7-10.7)Body mass indexkg/m^2^37 (32.5-43.5)Active smoking18 (35)Self-managementScoreOverall score (scale 0 to 104)82 (72--91)Knowledge of medications (scale 0 to 8)6 (5--8)Knowledge of condition (scale 0 to 8)6 (4--7)Medication adherence (scale 0 to 8)8 (5--8)Healthy lifestyle (scale 0 to 8)6 (4--8)Prescribed aspirin%31 (60)Prescribed ACEi / ARBs%45 (87)Prescribed HMG-CoA reductase inhibitors%32 (62)Number of prescribed anti-hypertensives*n*2 (1--3)All data are presented as n (%) or median (IQR).Table 2**Frequency of New Zealand deprivation scores** Deprivation scoreFrequencyPercentCumulative percent111.92.0211.94.0311.96.0411.98.0711.910.0835.816.091325.042.0102955.8100.0Total5096.2Missing23.8Total52100.0

Course and success in implementation of intervention {#Sec10}
----------------------------------------------------

Attendance of both the NP and the practice nurse was required as an integral component of the study intervention, and was 100% for the combined clinics. Staff satisfaction was surveyed as a routine part of clinical operations at the primary care practices, and was reported as high for all practice nurses and GPs involved in this initiative. All patients who were lost to follow up either died, withdrew due to severe intercurrent illness (one stroke, one myocardial infarction), or moved out of the district. 'Did not attend' rates were less than 5% for all participants remaining eligible over the entire period of observation.

Outcomes {#Sec11}
--------

Results of regression modelling and rank sum testing for study outcomes are provided in detail in Table [3](#Tab3){ref-type="table"}.Table 3**Change in observed outcome as a function of time**Primary outcomeChange per unit per month (linear), or change in odds ratio per month (binary categories)(95% Confidence Interval)P ValueACR−6.75−10.98, −2.520.002**Secondary outcomes**Estimated GFR−0.34−0.55, −0.120.0025-year absolute cardiovascular risk−0.24−0.40, −0.090.002**"Intermediary" secondary outcomes - participant**Systolic blood pressure (mmHg)−1.65−2.02, −1.28\<0.01Diastolic blood pressure (mmHg)−1.07−1.33, −0.81\<0.001Serum total cholesterol (mmol/L)−0.05−0.08, −0.020.002HbA1c (%)−0.09−0.13, −0.06\<0.001BMI (kg/m^2^)−0.06-.13, −0.0080.08Active smoking (odds ratio)0.690.54, 0.880.003Self-managementOverall score (scale 0 to 104)1.110.72, 1.50\<0.001Knowledge of medications (scale 0 to 8)0.170.12, 0.22\<0.001Knowledge of condition (scale 0 to 8)0.140.10, 0.18\<0.001Medication adherence (scale 0 to 8)0.050.001, 0.090.044Healthy lifestyle (scale 0 to 8)0.060.02, 0.110.005**"Intermediary" secondary outcomes - provider**Prescribed aspirin (odds ratio)1.611.23, 2.11\<0.001Prescribed ACEi/ARB (odds ratio)1.971.04, 3.720.037Prescribed HMG-CoA reductase inhibitors (odds ratio)1.261.08, 1.460.003Number of prescribed anti-hypertensives0.050.03, 0.07\<0.001

There was a significant change in the primary outcome, ACR, over the course of the study, amounting to an average decrease of −6.75 mg/mmol per month over the period of observation. There were also significant changes in the secondary outcomes. There was a significance decrease in estimated GFR of −0.3 mL/min/1.73 m^2^ per month, indicating that progression of CKD was still occurring within the study cohort amounting to a loss of 3--4 mL/min/1.73 m^2^ per annum. There was a significant decrease in the 5 year absolute cardiovascular risk by −0.2% per month. Changes in these primary and secondary outcomes are illustrated in Figure [2](#Fig2){ref-type="fig"}.Figure 2**Primary and secondary outcomes: albumin to creatinine ratio (mg/mmol), estimated GFR (mL/min/1.73 m** ^**2**^ **) and 5 year absolute cardiovascular risk (%) over the period of observation.** Individual participant trajectories are illustrated in the overlaid line plots in the left panels, and the trajectory for the cohort in the boxplots in the right panels (the central line represents the median, the box the first and third quartile, and the whiskers 1.5 × the interquartile range).

There were significant changes in intermediary secondary outcomes related to the participant. Blood pressure decreased significantly over the course of the study, with a median baseline measurement of 150/90 and a corresponding 12 month measurement of 132/76. Serum total cholesterol and HbA1c also decreased significantly, with median baseline measurements of 5.25 mmol/L and 8.75%, respectively, and corresponding 12 month measurements of 4.6 mmol/L and 7.55%, respectively. Adherence to lifestyle advice improved, with a significant decrease of active smoking from 35% to 10%, although there was no significant change in BMI. Self-management significantly improved across all relevant domains, with an increase in median overall self-management score from 82 to 99 over the period of observation. These changes are illustrated in Figures [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"} and [5](#Fig5){ref-type="fig"}.Figure 3**'Intermediary' secondary outcomes related to the patient: BP (mmHg), serum total cholesterol, BMI (kg/m** ^**2**^ **), HbA1c (%), prevalence of active smoking over the period of observation.** For continuous variables, individual participant trajectories are illustrated in the overlaid line plots in the left panels, and the trajectory for the cohort in the boxplots in the right panels (the central line represents the median, the box the first and third quartile, and the whiskers 1.5 × the interquartile range). For categorical variables, bar plots indicate proportions for the entire cohort.Figure 4**'Intermediary' secondary outcomes related to the patient: self-management, medical knowledge (knowledge of condition and medication), adherence to medication, and adoption of a healthy lifestyle over the period of observation.** Individual participant trajectories are illustrated in the overlaid line plots in the left panels, and the trajectory for the cohort in the boxplots in the right panels (the central line represents the median, the box the first and third quartile, and the whiskers 1.5 × the interquartile range).Figure 5**'Intermediary' secondary outcomes related to the provider: prescription of angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB), aspirin and lipid lowering medications, and number of antihypertensive medications.** For continuous variables, individual participant trajectories are illustrated in the overlaid line plots in the left panels, and the trajectory for the cohort in the boxplots in the right panels (the central line represents the median, the box the first and third quartile, and the whiskers 1.5 × the interquartile range). For categorical variables, bar plots indicate proportions for the entire cohort.

There were significant changes in intermediary secondary outcomes related to the provider. The prescription of ACEi/ARBs, aspirin and lipid lowering medications, increased significantly to 97%, 86%, and 80% respectively. The mean number of prescribed anti-hypertensives increased significantly from 2 to 3.

Discussion {#Sec12}
==========

This report evaluates a primary care based intervention for CKD patients at high risk of CKD progression. The intervention utilized the nephrology NP within this setting to improve risk factors for progression of CKD. The baseline data for this group of participants indicated sub-optimal management for an extended period of time, with clinical care and outcomes that were not meeting customary targets suggested in clinical practice guidelines. Such characteristics define a common, problematic group of patients, both within New Zealand and internationally. One study from the United Kingdom typifies this experience, with only a fifth of those with diabetes and CKD having a BP of 130/80 mmHg or less, and fewer than half on angiotensin-converting-enzyme inhibitor or angiotensin-receptor blocker \[[@CR30]\]. Similar findings have been reported from the United States \[[@CR31]\].

This study supports the feasibility and potential effectiveness of an integrated model of care for management of CKD. During the course of the nurse-led intervention there was improved control of accepted risk factors for progression of CKD. Patient adherence to medication and lifestyle advice both improved over the duration of the intervention, indicating that high risk patients are sometimes willing to engage in lifestyle modifications when afforded adequate support and education about management of their condition, combined with empowerment through improved self-management skills.

Several other studies have shown similar success. An algorithm-based, primary care disease-management programme for patients with CKD in the United Kingdom also associated with better control of BP, lower serum cholesterol, and reduced the rate of kidney function loss supporting the notion of a community based model of care as being both efficacious and cost-effective \[[@CR32]\]. A community based (but not primary care based) initiative within New Zealand has also reported similar results in this population, with improvements in both renal and cardiac endpoints \[[@CR33]\]. A RCT involving intensified NP involvement reduced the decline in kidney function and improved renal outcomes in patients with prevalent CKD over a sustained follow-up period \[[@CR13]\].

The intervention described in this study involved collaboration between the regional secondary nephrology service and primary care practices. The nephrology NP worked primarily with practice nurses in the GP practices, with liaison with GPs as required. Interactions between these clinicians allowed for education around best practice and evidence-based management of CKD, and provided opportunities for learning through case reviews. This collaborative model also had the effect of enhancing the currently limited linkages between these primary care practices and the secondary nephrology service in the region.

There is no study in the literature that can be used to determine effect size between improved self-management and improved clinical outcomes. Other studies have assessed self-management as an outcome in itself, but only two have assessed effect on patient-centred outcomes such as HRQoL \[[@CR34], [@CR35]\]. Ours is the first to have assessed effect on clinical outcomes. One could question the clinical significance of the small improvement in self-management that we observed in this study, although we note that as with other studies that there is sustained improvement of clinical markers over time, suggesting a sustained and long-term effect that might persist and even increase beyond the period of observation in this study \[[@CR13]\]. The improvement in clinical outcomes observed in this study are small but significant. For instance, although the decrease in the 5 year absolute cardiovascular risk seems small at −0.2% per month, this is equivalent to a 1.2% annual decrease in the risk of a cardiovascular event for this study sample. This effect should be considered in the light of the global burden of diabetic patients with CKD, which is the primary diagnosis causing kidney disease in 20--40% of people starting treatment for ESKD \[[@CR36]\]. The rates of progression of newly diagnosed type 2 diabetics between the stages of normoalbuminuria, microalbuminuria, macroalbuminuria and kidney failure are 2--3% per year, as evidences in the United Kingdom Prospective Diabetes Study \[[@CR37]\]. The annual mortality rate in this population is approximately 7% \[[@CR38]\], and at least 50% of these deaths will be cardiovascular in nature. As such, a seemingly small 1-2% annual decrease in the risk of cardiovascular morbidity and mortality has the potential to avert many life-years lost, and many health-dollars spent.

The total cost of the pilot was \$160,000 over two years, this included; NP and practice nurse release time, payment for GP's and nurses to attend regular planning meetings, patient transport, blood tests, administration costs, clinical and electronic equipment and support, printing and development of resources, administration and reporting time. A large proportion of the cost was used in planning the pilot in the six months prior. Further studies should provide more detailed cost benefit analysis.

The success of the intervention suggests a goal for secondary nephrology services, in using their expertise to up-skill primary care clinicians to better manage CKD. There are several ways in which primary care practices can limit the growth of ESKD. Most importantly, practices can better screen their patient populations to identify those at different levels of risk, and work to apply evidence-based medicine to improve risk factor management amongst those with CKD. There are several major financial barriers to the scaling and implementation of programs such as the intervention in this study. The main ones relate to the impact on primary health care clinicians' work, and the corresponding impact for nephrology NPs who spend time away from their customary duties in secondary care. Self-management education should be included in all aspects of primary care and CKD management as they have proven successful in improving adherence outcomes in other chronic conditions \[[@CR39], [@CR40]\].

As a pilot intervention, this nurse-led intervention has potential to limit growth of expensive renal replacement therapy programmes. However, it was supported on a time-limited basis by the New Zealand Ministry of Health, with funding primarily to allow deployment of a clinical resource, the nephrology NP, from secondary into primary care. The service was therefore free to the patients enrolled in the intervention, which we assume contributed to their compliance with the requirements of the programme. The feasibility of reproducing this pilot on a larger scale with an economic benefit would need to be further explored in future research. Making publicly subsidized funding of primary care contingent on clinical outcomes for practice populations may be required to incentivize adoption of different clinical activities. Financial incentive schemes employed in the United Kingdom have been shown to potentially contribute to the reduction in health inequalities in deprived areas \[[@CR41]\].

There are several limitations of study design. Firstly, this study is a quality improvement initiative rather than a randomized controlled trial, with no comparator group or clinical data from the period prior to the intervention. As such, there is risk of bias and confounding, and no absolute certainty that the improvements were the direct results of the intervention. It is possible that they arose due to a separate and unrecognized co-intervention. It is also plausible that the improvements arose from "regression to the mean" in our study sample, which can occur when subjects are selected with outcome measures at the extremes of a given distribution. In this situation, the measures will tend to be closer to the centre of the distribution on subsequent measurements, which can often be incorrectly inferred as being an improvement in response to an intervention. The sampling frame in this study (non-adherence over the prior one-year period) reduces the risk of this occurrence, although it remains a very definite, unquantifiable limitation on the interpretation of our results. The second limitation of the study design is that it is a small-scale project, and cannot therefore be considered as proof of clinical effectiveness and cost effectiveness. Instead, the study demonstrates the feasibility of this approach and potential effectiveness. Finally, the study design did not include data collection to evaluate change in the organizational or clinical culture in primary care clinicians outside of the intervention. As such, it is not possible to evaluate whether the intervention was effective in institutionalizing a change in culture towards quality improvement in CKD care \[[@CR42]\].

There are several limitations of study analyses that should also be acknowledged. Firstly, these were not performed in a way that allowed for causal inference, which would be the required approach to answer questions such as "did changes in proteinuria result from greater prescription of medication, or rather the improved compliance of said medication?". Such analyses may be possible using various structural modelling approaches, and will be considered further in the future. Secondly, analyses assume linear relationships over time, a prosaic approach to improve comprehensibility of the statistical models. The analyses cannot, however, address any non-linear relationships that might have occurred over the period of observation. For instance, the changes in many study variables show a pronounced early improvement, with some "rebound" at a later time. Notwithstanding, the models in this study do provide an indication of the overall effect of the intervention over the course of the study, and strongly suggest that the benefits observed over 3 months were sustained to a significant degree during the remainder of the 12 months follow-up. Future studies are planned to identify co-morbidities within the source population of our study sample, to compare multi-morbidity between the groups.

Conclusions {#Sec13}
===========

This study demonstrates that a model of specialist nephrology NP led clinics with primary care clinicians is feasible and may improve risk factors for progression of CKD and cardiovascular death. The cost of implementing such as program a wider basis would be considerable, although costs maybe offset in the long-term if the future burden of ESKD is reduced. Notwithstanding, a collaborative approach to primary and secondary care may be an effective way to manage high risk patients with CKD in the primary care setting. The results of this study call for definitive studies to definitively determine the effectiveness and costs of this intervention in a controlled study on a wider scale.
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